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A randomised trial of robotic and open
prostatectomy in men with localised prostate
cancer
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Rob Carter5, Scott Williams6, Robyn J Medcraft1,2, Nigel Bennett1, Martin F Lavin1,7 and
Suzanne Kathleen Chambers1,3,4,8

Abstract
Background: Prostate cancer is the most common male cancer in the Western world however there is ongoing
debate about the optimal treatment strategy for localised disease. While surgery remains the most commonly
received treatment for localised disease in Australia more recently a robotic approach has emerged as an
alternative to open and laparoscopic surgery. However, high level data is not yet available to support this as a
superior approach or to guide treatment decision making between the alternatives. This paper presents the design
of a randomised trial of Robotic and Open Prostatectomy for men newly diagnosed with localised prostate cancer
that seeks to answer this question.
Methods/design: 200 men per treatment arm (400 men in total) are being recruited after diagnosis and before
treatment through a major public hospital outpatient clinic and randomised to 1) Robotic Prostatectomy or 2)
Open Prostatectomy. All robotic prostatectomies are being performed by one surgeon and all open
prostatectomies are being performed by one other surgeon. Outcomes are being measured pre-operatively and at
6 weeks and 3, 6, 12 and 24 months post-surgery. Oncological outcomes are being related to positive surgical
margins, biochemical recurrence +/− the need for further treatment. Non-oncological outcome measures include:
pain, physical and mental functioning, fatigue, summary (preference-based utility scores) and domain-specific QoL
(urinary incontinence, bowel function and erectile function), cancer specific distress, psychological distress, decisionrelated distress and time to return to usual activities. Cost modelling of each approach, as well as full economic
appraisal, is also being undertaken.
Discussion: The study will provide recommendations about the relative benefits of Robotic and Open
Prostatectomy to support informed patient decision making about treatment for localised prostate cancer; and to
assist in treatment services planning for this patient group.
Trial registration: ACTRN12611000661976

Background
Because of an absence of objective information from
randomised studies, it is advised that men diagnosed
with localised prostate cancer (PCa) are offered three
broad treatment approaches that include surgery or radical prostatectomy (RP), irradiation of the prostate, or
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observation in the form of active surveillance or watchful waiting [1]. In practice, however, multiple options are
often presented that arise not only through treating clinicians, but from family, friends, the media, and self-help
programs [2]. The option list can then include an array
such as open, laparoscopic & robotic RP, external beam
radiation, high and low-dose brachytherapy, high frequency focussed ultrasound, a variety of alternative therapies and monitoring. For each approach, the newly
diagnosed man must consider costs and benefits from a
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survival and quality of life (QoL) point of view, financial
costs and relative availabilities.
In this decision context, high quality evidence about
the expected outcomes of each approach is essential
however, problematic for robotic procedures, this information is lacking. Specifically, data on QoL outcomes
comparing robotic procedures with open RP are typically from case series from single centres [3-6], with, to
our knowledge, only one other randomised controlled
trial being undertaken, comparing open, laparoscopic
and robotic prostatectomy (the LopeRA study) which is
experiencing difficulty recruiting patients [7,8]. This
paucity of high-quality information leaves men with
localised prostate cancer, and their physicians, in the
difficult position of trying to make a treatment decision
without high quality evidence. Moreover there is evidence that once robotic surgery becomes available, consumer demand drives up its usage, with one study
reporting that during the course of a case series to
compare robotics with other approaches, at the study
completion more than 94% of men had chosen robotic
surgery [5]. This means there are also health services
planning and delivery issues that arise from this evidence gap.
To date, case series suggest varied outcomes when
comparing robotic with open RP. Some suggest that
patients who undergo robotic surgery have less postoperative narcotic use, shorter hospital stays [6] and better short term urinary and sexual function [3,5]. Other
studies have found no clear differences in functional outcomes with regards to potency, continence [9], pain and
recovery [10]. Finally, the methodological issues that ensue from selection bias in case series and the use of
non-standard reporting methods make much of this data
difficult to interpret [4,11].
The present study will address this knowledge gap by
completing the first randomised trial with men with
localised prostate cancer comparing robotic with open
RP and assessing QoL and psychosocial outcomes using
reliable and previously validated measures of pain, physical and mental functioning, fatigue, summary (preference-based utility scores) and domain-specific QoL
(urinary incontinence, bowel function and erectile function), cancer specific distress, psychological distress,
decision-related distress and time to return to usual activities. Outcomes are being measured pre-operatively
and at 6 weeks and 3, 6, 9, 12, 18 and 24 months postsurgery. Co-morbidity is being considered as a critical
issue in deciding who may ultimately benefit from treatment. An economic evaluation is addressing the question of whether open or robotic RP is better ‘value-formoney’, having regard to their comparative costs and
outcomes [12-14]. The economic model is integrating
the surgical/clinical indices and QoL data from the trial,
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with the resource costs of the inputs necessary to implement both intervention arms.

Methods/design
Study aims and hypotheses

The study aims are to assess the quality of life effects of
robotic surgery compared with open prostatectomy; determine the economic costs of robotic versus open prostatectomy with regards to both health sector costs and
direct and indirect cost to patients; evaluate life expectancy profiles of patients receiving both forms of
prostatectomy.
We hypothesise that:
1. There will be no difference between the two groups
in terms of surgical and clinical indices of oncological
outcome.
2. Patients randomised to robotic prostatectomy will
have improved short term (3 months postoperative)
quality of life outcomes compared with those
randomised to open prostatectomy with regards to
pain, physical functioning, fatigue; summary (AQoL8D and SF36) and domain specific quality of life
(urinary incontinence, bowel function and erectile
function), time to return to usual activities.
3. Patients randomised to open prostatectomy will have
comparable medium (6–12 months) and long term
(24 months) quality of life outcomes compared with
those randomised to robotic prostatectomy with
regards to pain, physical functioning, fatigue;
summary (AQoL-8D and SF36) and domain specific
quality of life (urinary incontinence, bowel function
and erectile function).
4. There will be no difference between the two groups
with regards to psychological distress, cancer specific
distress and decision-related distress.
5. There will be a short-term and overall cost advantage
for open prostatectomy.
Men are being recruited via the Royal Brisbane and
Women’s Hospital (RBWH) Urology Outpatient Clinic
and urologists’ private practices. Inclusion criteria are
that the men must: (1) be newly diagnosed with localised
PCa and have chosen surgery as their treatment approach (2) be able to read and speak English (3) have no
previous history of head injury, dementia or psychiatric
illness (4) have no other concurrent cancer. Following a
pilot study of 69 patients earlier in 2010, recruitment
commenced in October of that year and is continuing to
allow for a total sample size of 400 men randomly allocated to either robotic RP or open RP. Since commencement of the definitive trial, we have recruited and
randomised 146 men, 141 of whom have had a radical
prostatectomy (73 = robotic; 68 = open). Five men
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randomised to open prostatectomy did not proceed in
the trial; two elected to have a robotic prostatectomy
privately, two had life-threatening cardiac problems following induction of anaesthesia such that the operation
was aborted and one had previous laparoscopic inguinal
hernia repairs using mesh so that access to the prostate
was severely compromised. All three proceeded to have
external beam radiation therapy, following neoadjunctive androgen deprivation therapy, with curative
intent. Patients are assessed at recruitment and before
treatment (baseline), then again at 6 weeks and 3, 6, 12
and 24 months post-surgery.
Study integrity

Ethical approval has been obtained from the RBWH
Human Research Ethics Committee. The study design is
guided by the CONSORT statement [15]. All men provide written informed consent. Assessments are by selfreport pen and paper measures with project staff tracking assessments. Randomisation occurs in blocks of 10,
with each condition randomly generated 5 times within
each block to ensure an unpredictable allocation sequence with equal numbers of men in each group at the
completion of each block. This sequence is undertaken
using a computerised database independent from the
clinical team and research staff. Stratification occurs by
age group (40–49 yrs, 50–59 yrs, 60-69 yrs); and IPSS
score (0–7, 8–19, 20–35). Following randomisation,
patients are telephoned the same day to be notified of
their designated surgical procedure and posted an information booklet outlining expectations for their scheduled operation. Following this, patients are placed on the
surgical waiting list at the RBWH and scheduled for surgery as per standard hospital procedures. Biopsy slides
are reviewed pre-operatively by staff pathologists JP-K,
JDP or MLTHS all of whom have recognised expertise in
uropathology.

Materials
QoL and other outcome assessments are being undertaken using a series of well-validated and reliable measures administered by pen and paper questionnaire.
Socio-demographic information is being collected at
time of recruitment by interview. Clinical diagnostic and
treatment information, including operative time, length
of hospital stay, blood loss, time to catheter removal, use
of narcotic analgesia and peri-operative complications
are being collected through medical record review. Pathology review is being undertaken centrally by our two
uropathologists to the trial in conjunction with MLTHS
and includes standardised evaluation of the Gleason
scoring using the 2005 ISUP classification, positive margins, extra prostatic capsular extension, neurovascular
and seminal vesicle involvement with quality control of
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selected sections by international pathologists. Prostatespecific antigen testing occurs 2–4 weeks preoperatively; then at 6 weeks, 3, 6, 9, 12, 18 and
24 months after surgery; and then annually. Biochemical
failure (bF) is diagnosed on the first occasion following
prostatectomy that the serum PSA is ≥0.2 ng/mL, after
which patients undergo total body bone scan and CT
scan of abdomen and pelvis for assessment of local and
distant failure. Patients are given adjuvant or salvage radiation therapy at the surgeon’s discretion. Clinical staging is being performed using the current UICC TNM
staging classification based on the outcome of biopsies,
digital rectal exam, transrectal ultrasonography (TRUS),
bone scan and contrast-enhanced computerised tomography (CT) pre-operatively. MRI is performed at the surgeon’s discretion. A CT scan of the pelvis and abdomen
with 8 mm-slices is performed to evaluate lymph nodes.
Pathological staging is being determined from histopathology of the radical prostatectomy specimen along with
the findings from lymph nodes with extended lymph
node dissection performed for patients with serum PSA
>10 ng/ml, primary Gleason ≥4 or cT2b or greater. Postoperative complications are being assessed through chart
review supplemented by discussion and letter sent with
the patient questionnaire according to the Clavien system of classification.
Self-report measures
Anxiety and depression

The Hospital Anxiety and Depression Scale (HADS;
[16]) is providing a measure of current psychological distress with subscale scores for anxiety and depression.
Psychological distress

The Revised Impact of Events Scale (IES-R [17]) is being
used to measure men’s cancer specific distress symptoms. The IES-R has three subscales: intrusion, avoidance and hyperarousal. Internal consistencies for the
IES-R subscales are good. Epping-Jordan [18] suggest
that intrusion and avoidance are more sensitive measures of psychological distress after a cancer diagnosis
than generalised distress measures. In men treated for
localised prostate cancer intrusion and avoidance have
been found to be related to poorer mental health outcomes [19].
Decision-related distress

For decision-related distress we assess both decisional
conflict and decision regret. The Decisional Conflict
Scale-Revised (DCS [20,21]) measures a person’s perception of the difficulty involved in making a decision about
medical treatments. The revised scale has 19 items covering decisional uncertainty, feeling uninformed, unclear
about personal values, and unsupported in decision
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making, and perceptions of effective decision making.
The DCS has been validated in a range of population
groups and is sensitive to people making different health
decisions, and to the effect of decision aids, with good
internal consistency for the total scale. Health decisions
assessed with this scale include treatment for localised
prostate cancer.
Domain specific QoL

Domain specific QoL is being measured by the EPIC,
the Expanded Prostate Cancer Index Composite [22]: 39
items from this measure will assess functioning in three
problem domains: urinary, sexual and bowel. Men are
also completing the International Index of Erectile Functioning (IIEF) [23], which allows sexual function to be
assessed in five domains: erectile function, orgasmic
function, sexual desire, intercourse satisfaction and overall sexual satisfaction. A scale developed by Schover [24]
is being used to assess whether men have obtained medical help for sexual dysfunction and the impact of each
treatment on their sex life.
Health related quality of life

Health related quality of life is being assessed with the
SF-36 that is the most widely used QOL measure in the
world with norms for the Australian general population
available. The SF-36 [25] contains a mental health and
physical health summary scale suitable to measure the
impact of the intervention on patients’ wellbeing. As
well, the Assessment of Quality of Life – 8D (AQoL-8D)
will be administered [26]. The AQoL-8D is a 35-item
scale assessing quality of life on eight dimensions including: independent living, relationships, mental health, self
worth, happiness, coping, pain, and sensory perception.
The AQoL-8D is the primary outcome instrument for
the economic appraisal, has excellent psychometric
properties and has been used in over 80 trials in
Australia.
Employment outcomes

Questions are being asked on pre-cancer and current
employment status, time off work, returning to work, receipt of sickness and other benefits, unpaid work activities, changes in work role, consequences at work due to
cancer, perceived work productivity, assistance from
family or others, and carer’s or partner’s work patterns
since the participant’s cancer diagnosis.
Prospective life expectancy modelling

A secondary analysis will identify the comorbidity index
which optimises prediction of death from causes other
than prostate cancer within 10 years of diagnosis of PCa.
We will use the ChI, age-adjusted ChI, ASA, number
of comorbid conditions, number of prescription
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medications (data collected as part of routine history
and examination on a proforma) and the TIBI-CaP (an
84 question questionnaire for the patient) as predictor
covariates. Time to death from comorbid conditions, as
well as from PCa, will be assessed at 5 and 10 years following trial closure. The discriminatory ability of various
indices will be assessed using concordance index of the
covariate (analogous to area under the ROC curve), with
statistical differences between models tested using Integrated Discrimination Index (IDI).
Economic appraisal

Costs are being assessed from a health sector perspective, covering impacts that fall on ‘government as 3rd
party funder’, as well as those affecting patients and their
families. Pathway analysis (incorporating decision tree
analysis) will be used to clearly identify the activity components for each arm of the trial, complemented by a
prospective patient-held cost diary covering the entire
trial period (week one to 24 months). The cost categories in the diary are those of travel costs, time costs and
productivity costs. Patients fill in the cost diary at one
week and then are discharged home with the diary to fill
out at home. At each visit patients return the completed
cost diary and collect the cost diaries relevant to the
next period of the trial.
Costs for each arm of the trial will be analysed by
components of the intervention pathway (e.g. pre-consultation, work-up, theatre, post-treatment, follow-up,
management/coordination, side-effects, etc.); by expenditure category (e.g. capital, staff, consumables, overheads,
other); and by incidence (i.e. who bears the costs). The
cost component of the economic appraisal will thus assess the cost drivers from a range of perspectives for
both intervention approaches. Downstream costs and
potential cost offsets incurred beyond the randomised
trial data collection period will be modelled from the literature and expert opinion, with sources clearly documented. Production gains/losses in the general economy
will be modelled based on data collections from the trial,
using methods developed by Deakin Health Economics
[27,28]. Cost-effectiveness results will be reported with
and without production effects included.
The economic appraisal will involve a cost effectiveness analysis (CEA), a cost consequences analysis (CSA)
and a cost utility analysis (CUA). Outcome measures in
the CSA will include incremental changes in the full
range of clinical/surgical and psychosocial variables, to
paint as comprehensive a picture as possible between resource usage and outcomes. In the CEA outcomes will
be reported as incremental cost per outcome ratios
(ICERs) for a select range of outcomes that have clinical
and/or policy relevance. ICERs will be reported for return to work, the EPIC (the 3 domains urinary, sexual
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and bowel) and the IIEF (the 5 domains of sexual function). In the CUA, outcomes will be reported as the ‘incremental cost per QALY’ (quality adjusted life year).
The AQol-8D will be used as the primary measure of
QoL in the economic appraisal, with secondary ICERs
developed for the SF-36. Consistency between the QoL
results from the AQoL-8D, the SF-36 and the other domain specific QoL measures collected in the trial will be
carefully assessed. Standard discounting will be applied
to both costs and outcomes, together with detailed sensitivity testing.
Statistical analyses

The study design involves a two group Randomised trial
with five assessment points. As the hypotheses involve
comparisons of the rate of change with which men in
the treatment versus control groups will achieve optimal
physical and psychological QoL, the appropriate analysis
is a two level multilevel model (with Level 2 = men and
Level 1 = Assessment points). These analyses will be
adjusted to account for equivalence testing procedures
where appropriate with respect to the hypotheses. Although power models are not articulated for multilevel
analysis as clearly as they are for ordinary linear modelling, the Optimal Design software of Raudenbush [29]
and the simulation work of Jo [30] suggest appropriate
sample sizes. Assuming that at least 70% of the men in
each group will remain in the study (this is highly conservative as we have previously demonstrated only a 10%
attrition rate in QoL studies with men with PCa) and assuming further moderate effect size of d = 0.5 and alpha
at .05, a total sample size if 400 (i.e. 200 per group)
would result in over 90% power.

Discussion
This research program is addressing key questions of
importance by evaluating robotic and open prostatectomy in terms of oncologic parameters, quality of life
effects including level of satisfaction, economic costs
and overall patient life expectancy; and more broadly by
establishing a gold standard for the evaluation of new
medical technologies in the clinical treatment of prostate
cancer in Australia and internationally. Outputs include
evidence to facilitate more effective decision making
about surgical treatment for localised prostate cancer
and information to support health service planning and
development for this rapidly growing patient group.
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